{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:49:48Z","timestamp":1785192588447,"version":"3.55.0"},"reference-count":352,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["777554"],"award-info":[{"award-number":["777554"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research and Innovation Foundation of Cyprus","award":["EXCELLENCE\/1216\/0092"],"award-info":[{"award-number":["EXCELLENCE\/1216\/0092"]}]},{"name":"Research and Innovation Foundation of Cyprus","award":["EXCELLENCE\/0421\/0086"],"award-info":[{"award-number":["EXCELLENCE\/0421\/0086"]}]},{"DOI":"10.13039\/501100007048","name":"EEA and Norway Grants","doi-asserted-by":"publisher","award":["New infrastructure for diagnosis and treatment of patients"],"award-info":[{"award-number":["New infrastructure for diagnosis and treatment of patients"]}],"id":[{"id":"10.13039\/501100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Advanced therapy medicinal products (ATMPs) are medicines for human use based on genes, cells or tissue engineering. After clear successes in adults, the nascent technology now sees increasing pediatric application. For many still untreatable disorders with pre- or perinatal onset, timely intervention is simply indispensable; thus, prenatal and pediatric applications of ATMPs hold great promise for curative treatments. Moreover, for most inherited disorders, early ATMP application may substantially improve efficiency, economy and accessibility compared with application in adults. Vindicating this notion, initial data for cell-based ATMPs show better cell yields, success rates and corrections of disease parameters for younger patients, in addition to reduced overall cell and vector requirements, illustrating that early application may resolve key obstacles to the widespread application of ATMPs for inherited disorders. Here, we provide a selective review of the latest ATMP developments for prenatal, perinatal and pediatric use, with special emphasis on its comparison with ATMPs for adults. Taken together, we provide a perspective on the enormous potential and key framework parameters of clinical prenatal and pediatric ATMP application.<\/jats:p>","DOI":"10.3390\/pharmaceutics14040793","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:01:34Z","timestamp":1649138494000},"page":"793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-9584","authenticated-orcid":false,"given":"Carsten W.","family":"Lederer","sequence":"first","affiliation":[{"name":"The Molecular Genetics Thalassemia Department, The Cyprus Institute of Neurology & Genetics, Nicosia 2371, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Koniali","sequence":"additional","affiliation":[{"name":"The Molecular Genetics Thalassemia Department, The Cyprus Institute of Neurology & Genetics, Nicosia 2371, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Buerki-Thurnherr","sequence":"additional","affiliation":[{"name":"Empa, Swiss Federal Laboratories for Materials Science and Technology, 9014 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-3119","authenticated-orcid":false,"given":"Panayiota L.","family":"Papasavva","sequence":"additional","affiliation":[{"name":"The Molecular Genetics Thalassemia Department, The Cyprus Institute of Neurology & Genetics, Nicosia 2371, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8026-0715","authenticated-orcid":false,"given":"Stefania","family":"La Grutta","sequence":"additional","affiliation":[{"name":"Institute of Translational Pharmacology, IFT National Research Council, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-6482","authenticated-orcid":false,"given":"Amelia","family":"Licari","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-097X","authenticated-orcid":false,"given":"Frantisek","family":"Staud","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kr\u00e1lov\u00e9, Charles University, 50005 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2636-9159","authenticated-orcid":false,"given":"Donato","family":"Bonifazi","sequence":"additional","affiliation":[{"name":"Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) and European Paediatric Translational Research Infrastructure (EPTRI), 70122 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kleanthous","sequence":"additional","affiliation":[{"name":"The Molecular Genetics Thalassemia Department, The Cyprus Institute of Neurology & Genetics, Nicosia 2371, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"ref_1","unstructured":"European Medicines Agency (2021, October 11). Advanced Therapy Medicinal Products: Overview|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/advanced-therapy-medicinal-products-overview."},{"key":"ref_2","unstructured":"European Medicines Agency (2021, October 11). Advanced Therapy Classification|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/advanced-therapies\/advanced-therapy-classification."},{"key":"ref_3","unstructured":"European Medicines Agency (2021, October 11). Guidelines Relevant for Advanced Therapy Medicinal Products|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/advanced-therapies\/guidelines-relevant-advanced-therapy-medicinal-products."},{"key":"ref_4","unstructured":"European Medicines Agency (2021, October 11). Marketing-Authorisation Procedures for Advanced-Therapy Medicinal Products|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/advanced-therapies\/marketing-authorisation-procedures-advanced-therapy-medicinal-products."},{"key":"ref_5","unstructured":"European Medicines Agency (2021, October 11). Niraparib|Medicines|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines?search_api_views_fulltext=cancer+niraparib."},{"key":"ref_6","unstructured":"(2021, October 11). EC Medicines for Children|EC Public Health. Available online: https:\/\/ec.europa.eu\/health\/human-use\/paediatric-medicines\/."},{"key":"ref_7","first-page":"683","article-title":"Regulatory considerations for gene therapy products in the US, EU, and Japan","volume":"90","author":"Peyer","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2020.11.008","article-title":"Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States","volume":"23","author":"Obach","year":"2021","journal-title":"Cytotherapy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1600939","DOI":"10.1080\/20016689.2019.1600939","article-title":"Technology forecast: Advanced therapies in late clinical research, EMA. approval or clinical application via hospital exemption","volume":"7","author":"Eder","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_10","unstructured":"Gatline, A. (2018, May 17). Investor\u2019s Business Daily\u00ae \u2013 Technology: Can CRISPR and These 3 Small Biotechs Cure 10,000 Diseases?. Available online: https:\/\/www.investors.com\/news\/technology\/crispr-gene-editing-biotech-companies\/."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Paniagua, M., de la Mata, A., Galindo, S., Bl\u00e1zquez, F., Calonge, M., and Nieto-Miguel, T. (2021). Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030347"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40545-021-00311-0","article-title":"Price and reimbursement of advanced therapeutic medicinal products in Europe: Are assessment and appraisal diverging from expert recommendations?","volume":"14","author":"Ronco","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13287-021-02222-y","article-title":"Human umbilical cord-derived mesenchymal stem\/stromal cells: A promising candidate for the development of advanced therapy medicinal products","volume":"12","author":"Mebarki","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bph.15305","article-title":"Developing cell therapies as drug products","volume":"178","author":"Ciccocioppo","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41434-019-0074-7","article-title":"Delivering cellular and gene therapies to patients: Solutions for realizing the potential of the next generation of medicine","volume":"27","author":"Elverum","year":"2020","journal-title":"Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Koniali, L., Lederer, C.W., and Kleanthous, M. (2021). Therapy Development by Genome Editing of Hematopoietic Stem Cells. Cells, 10.","DOI":"10.3390\/cells10061492"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/bcp.14781","article-title":"Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU","volume":"87","author":"Whomsley","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lechanteur, C., Briquet, A., Bettonville, V., Baudoux, E., and Beguin, Y. (2021). Msc manufacturing for academic clinical trials: From a clinical-grade to a full gmp-compliant process. Cells, 10.","DOI":"10.3390\/cells10061320"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1089\/hum.2021.058","article-title":"Call for more effective regulation of clinical trials with advanced therapy medicinal products consisting of or containing genetically modified organisms in the European Union","volume":"32","author":"Beattie","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_20","unstructured":"European Medicines Agency (2021, December 10). Scientific Recommendations on Classification of Advanced Therapy Medicinal Products|EMA\/140033\/2021. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/advanced-therapies\/advanced-therapy-classification\/scientific-recommendations-classification-advanced-therapy-medicinal-products."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s40472-018-0202-0","article-title":"Approaches for Effective Clinical Application of Stem Cell Transplantation","volume":"5","author":"Attico","year":"2018","journal-title":"Curr. Transplant. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jval.2019.03.014","article-title":"Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System","volume":"22","author":"Quinn","year":"2019","journal-title":"Value Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/humc.2018.201","article-title":"The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost","volume":"30","author":"Shukla","year":"2019","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ltab004","DOI":"10.1093\/immadv\/ltab004","article-title":"An overview of CAR T-cell clinical trial activity to 2021","volume":"1","author":"Adami","year":"2021","journal-title":"Immunother. Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Li, Y.-R., Dunn, Z.S., Zhou, Y., Lee, D., and Yang, L. (2021). Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies. Cells, 10.","DOI":"10.3390\/cells10123497"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1196\/annals.1345.007","article-title":"A phase I\/II clinical trial of beta-globin gene therapy for beta-thalassemia","volume":"1054","author":"Bank","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia","volume":"467","author":"Payen","year":"2010","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene Therapy in a Patient with Sickle Cell Disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene Therapy in Patients with Transfusion-Dependent \u03b2-Thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","unstructured":"CRISPRTX (2021, June 01). CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results. Available online: http:\/\/ir.crisprtx.com\/news-releases\/news-release-details\/crispr-therapeutics-provides-business-update-and-reports-4."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1097\/MPH.0000000000001758","article-title":"Extended Treatment with Mesenchymal Stromal Cells-Frankfurt am Main in a Pediatric Patient with Steroid-refractory Acute Gastrointestinal Graft-Versus-Host Disease: Case Report and Review of the Literature","volume":"43","author":"Gruhn","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Buscail, E., Le Cosquer, G., Gross, F., Lebrin, M., Bugarel, L., Deraison, C., Vergnolle, N., Bournet, B., Gilletta, C., and Buscail, L. (2021). Adipose-derived stem cells in the treatment of perianal fistulas in Crohn\u2019s disease: Rationale, clinical results and perspectives. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189967"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcyt.2018.09.010","article-title":"Cell, tissue and gene products with marketing authorization in 2018 worldwide","volume":"20","author":"Cuende","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T cells: Building on the CD19 paradigm","volume":"51","author":"Eshhar","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2021.249","article-title":"CD19 or CD20 CAR T-cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with CNS Lymphoma","volume":"33","author":"Liu","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"607362","DOI":"10.3389\/fonc.2020.607362","article-title":"CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin\u2019s Lymphoma","volume":"10","author":"Xue","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, H., Liu, M., Xiao, X., Lv, H., Jiang, Y., Li, X., Yuan, T., and Zhao, M. (2022). A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. Leuk. Lymphoma, 1\u201310.","DOI":"10.1080\/10428194.2022.2030476"},{"key":"ref_43","first-page":"2183","article-title":"CAR T cell therapy: A new era for cancer treatment (Review)","volume":"42","author":"Mohanty","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ymthe.2020.11.020","article-title":"Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases","volume":"29","author":"Tucci","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bit.25008","article-title":"Allogeneic cell therapy bioprocess economics and optimization: Single-use cell expansion technologies","volume":"111","author":"Simaria","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40291-019-00392-3","article-title":"Rare Opportunities: CRISPR\/Cas-Based Therapy Development for Rare Genetic Diseases","volume":"23","author":"Papasavva","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"618346","DOI":"10.3389\/fgeed.2021.618346","article-title":"The Promise and the Hope of Gene Therapy","volume":"3","author":"Papanikolaou","year":"2021","journal-title":"Front. Genome Ed."},{"key":"ref_51","unstructured":"European Medicines Agency (2022, March 21). Zynteglo. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zynteglo."},{"key":"ref_52","unstructured":"European Medicines Agency (2022, March 21). Skysona. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skysona."},{"key":"ref_53","unstructured":"European Medicines Agency (2022, March 21). Strimvelis. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/strimvelis."},{"key":"ref_54","unstructured":"European Medicines Agency (2022, March 21). Libmeldy. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libmeldy."},{"key":"ref_55","unstructured":"European Medicines Agency (2022, March 21). Luxturna. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/luxturna."},{"key":"ref_56","unstructured":"European Medicines Agency (2022, March 21). Zolgensma. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma."},{"key":"ref_57","unstructured":"European Medicines Agency (2022, March 21). Resamirigene Bilparvovec. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-002571-pip01-19."},{"key":"ref_58","first-page":"557","article-title":"Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use","volume":"16","author":"Lazarus","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-2-35","article-title":"Acute graft versus host disease","volume":"2","author":"Jacobsohn","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/thoraxjnl-2011-201309","article-title":"Mesenchymal stem cell therapy in acute lung injury: Is it time for a clinical trial?","volume":"67","author":"McAuley","year":"2012","journal-title":"Thorax"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1704400","article-title":"Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation","volume":"33","author":"Maitra","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","article-title":"Treatment of graft versus host disease with mesenchymal stromal cells: A phase I study on 40 adult and pediatric patients","volume":"20","author":"Introna","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study","volume":"371","author":"Frassoni","year":"2008","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"McIntyre, L.A., Moher, D., Fergusson, D.A., Sullivan, K.J., Mei, S.H.J., Lalu, M., Marshall, J., McLeod, M., Griffin, G., and Grimshaw, J. (2016). Efficacy of mesenchymal stromal cell therapy for acute lung injury in preclinical animal models: A systematic review. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147170"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1165\/rcmb.2004-0330OC","article-title":"Bone marrow-derived mesenchymal stem cells in repair of the injured lung","volume":"33","author":"Rojas","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_67","first-page":"46","article-title":"BOOSTB4 (Boost Brittle Bones before Birth) trial protocol","volume":"40","author":"Sagar","year":"2020","journal-title":"Prenat. Diagn."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jcyt.2017.09.012","article-title":"Extracellular vesicles released from mesenchymal stromal cells stimulate bone growth in osteogenesis imperfecta","volume":"20","author":"Otsuru","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2041731420926918","article-title":"Engineered scaffolds based on mesenchymal stem cells\/preosteoclasts extracellular matrix promote bone regeneration","volume":"11","author":"Dong","year":"2020","journal-title":"J. Tissue Eng."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/(SICI)1097-4636(20000305)49:3<328::AID-JBM5>3.0.CO;2-Q","article-title":"Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones","volume":"49","author":"Kon","year":"2000","journal-title":"J. Biomed. Mater. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/107632704322791871","article-title":"Bone Tissue Engineering for Spine Fusion: An Experimental Study on Ectopic and Orthotopic Implants in Rats","volume":"10","author":"Dhert","year":"2004","journal-title":"Tissue Eng."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4252\/wjsc.v14.i1.54","article-title":"Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications","volume":"14","author":"Vicinanza","year":"2022","journal-title":"World J. Stem Cells"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Harrell, C.R., Volarevic, A., Djonov, V.G., Jovicic, N., and Volarevic, V. (2021). Mesenchymal stem cell: A friend or foe in anti-tumor immunity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212429"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ebiom.2015.03.020","article-title":"Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells","volume":"2","author":"Premer","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.21037\/atm-21-2885","article-title":"Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis","volume":"9","author":"Liu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e12872","DOI":"10.7717\/peerj.12872","article-title":"From hair to liver: Emerging application of hair follicle mesenchymal stem cell transplantation reverses liver cirrhosis by blocking the TGF-\u03b2\/Smad signaling pathway to inhibit pathological HSC activation","volume":"10","author":"Liu","year":"2022","journal-title":"PeerJ."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13287-021-02289-7","article-title":"Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases","volume":"12","author":"Huang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/sctm.19-0044","article-title":"Challenges in Clinical Development of Mesenchymal Stromal\/Stem Cells: Concise Review","volume":"8","author":"Mastrolia","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/crispr.2019.0029","article-title":"Controlling CRISPR Through Law: Legal Regimes as Precautionary Principles","volume":"2","author":"Sherkow","year":"2019","journal-title":"Cris. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMp1900504","article-title":"After the Storm\u2014A Responsible Path for Genome Editing","volume":"380","author":"Daley","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/rme-2021-0026","article-title":"Comparability: What we can learn from the review of advanced therapy medicinal products","volume":"16","author":"Cockroft","year":"2021","journal-title":"Regen. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcyt.2018.03.038","article-title":"A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making","volume":"20","author":"Coppens","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"755052","DOI":"10.3389\/fphar.2021.755052","article-title":"Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries","volume":"12","author":"Gozzo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2018.10.003","article-title":"Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe","volume":"11","author":"Hoekman","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2174\/1566523217666170119113029","article-title":"Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia","volume":"16","author":"Adair","year":"2017","journal-title":"Curr. Gene Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Jossen, V., Muoio, F., Panella, S., Harder, Y., Tallone, T., and Eibl, R. (2020). An approach towards a gmp compliant in-vitro expansion of human adipose stem cells for autologous therapies. Bioengineering, 7.","DOI":"10.3390\/bioengineering7030077"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Agostini, F., Vicinanza, C., Biolo, G., Spessotto, P., Da Ros, F., Lombardi, E., Durante, C., and Mazzucato, M. (2021). Nucleofection of Adipose Mesenchymal Stem\/Stromal Cells: Improved Transfection Efficiency for GMP Grade Applications. Cells, 10.","DOI":"10.3390\/cells10123412"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40199-020-00358-5","article-title":"Short and long term impacts of COVID-19 on the pharmaceutical sector","volume":"28","author":"Ayati","year":"2020","journal-title":"DARU J. Pharm. Sci."},{"key":"ref_89","unstructured":"Plieth, J. (2021, December 31). The $100,000 Problem Gene Therapy Companies Would Rather Not Mention|Evaluate. Available online: https:\/\/www.evaluate.com\/vantage\/articles\/analysis\/vantage-points\/100000-problem-gene-therapy-companies-would-rather-not."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10198-019-01147-x","article-title":"Advanced therapy medicinal products: Value judgement and ethical evaluation in health technology assessment","volume":"21","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"ref_91","unstructured":"(2021, May 18). BioPharma Dive. Available online: https:\/\/www.biopharmadive.com\/news\/bluebird-withdraw-zynteglo-germany-price\/598689\/."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3389\/fimmu.2020.00588","article-title":"Mechanisms of Fetal T Cell Tolerance and Immune Regulation","volume":"11","author":"Rackaityte","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molmed.2021.05.007","article-title":"In Utero Gene Therapy: Progress and Challenges","volume":"27","author":"Bose","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_94","unstructured":"European Medicines Agency (2021, October 11). Paediatric Regulation|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/paediatric-medicines\/paediatric-regulation."},{"key":"ref_95","unstructured":"(2022, February 24). EUR-Lex-32006R1901-EN-EUR-Lex. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32006R1901."},{"key":"ref_96","unstructured":"(2022, February 24). EUR-Lex-32006R1902-EN-EUR-Lex. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32006R1902."},{"key":"ref_97","unstructured":"European Commission (2017). State of Paediatric Medicines in the EU \u2013 10 Years of the EU Paediatric Regulation, European Commission. COM(2017)626."},{"key":"ref_98","unstructured":"European Medicines Agency (2017). 10-Year Report to the European Commission \u2013 General Report on the Paediatric Regulation, European Medicines Agency. EMA\/231225\/2015."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/hum.2007.120","article-title":"Factors determining the risk of inadvertent retroviral transduction of male germ cells after in utero gene transfer in sheep","volume":"20","author":"Park","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1038\/mtm.2016.20","article-title":"In utero stem cell transplantation and gene therapy: Rationale, history, and recent advances toward clinical application","volume":"3","author":"Atala","year":"2016","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biocel.2018.09.016","article-title":"Trophoblast: The central unit of fetal growth, protection and programming","volume":"105","author":"Staud","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"113950","DOI":"10.1016\/j.addr.2021.113950","article-title":"Targeted drug delivery for maternal and perinatal health: Challenges and opportunities","volume":"177","author":"Sharma","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.transproceed.2006.12.019","article-title":"Stem Cell Transplantation: The Lung Barrier","volume":"39","author":"Schrepfer","year":"2007","journal-title":"Transplant. Proc."},{"key":"ref_104","unstructured":"Nijagal, A., Le, T., Wegorzewska, M., and MacKenzie, T.C. (2010). A mouse model of in Utero transplantation. J. Vis. Exp., e2303."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ymthe.2017.04.003","article-title":"In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model","volume":"25","author":"Mattar","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.addr.2020.11.002","article-title":"Delivery technologies for in utero gene therapy","volume":"169","author":"Palanki","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_107","unstructured":"European Medicines Agency (2018, November 08). EMEA\/273974\/2005-Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products. Available online: https:\/\/www.ema.europa.eu\/."},{"key":"ref_108","unstructured":"European Commission (2019). Guidelines on Good Clinical Practice specific to Advanced Therapy Medicinal Products, European Commission. C(2019)7140."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.111.026120","article-title":"Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: Results of a nonrandomized multicenter study","volume":"124","author":"Jaeggi","year":"2011","journal-title":"Circulation"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"166206","DOI":"10.1016\/j.bbadis.2021.166206","article-title":"HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity","volume":"1867","author":"Cerveny","year":"2021","journal-title":"Biochim. Biophys. Acta-Mol. Basis Dis."},{"key":"ref_111","first-page":"S48","article-title":"The Path to Perfect Pediatric Posology\u2014Drug Development in Pediatrics","volume":"58","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_112","unstructured":"Manual, R., and Ray, L. (2007). Breeding Strategies for Maintaining Colonies of Laboratory Mice: A Jackson Laboratory Resource Manual, The Jackson Laboratory."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ayuso, M., Buyssens, L., Stroe, M., Valenzuela, A., Allegaert, K., Smits, A., Annaert, P., Mulder, A., Carpentier, S., and Van Ginneken, C. (2021). The neonatal and juvenile pig in pediatric drug discovery and development. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010044"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/gt.2010.47","article-title":"Large animal models of hematopoietic stem cell gene therapy","volume":"17","author":"Trobridge","year":"2010","journal-title":"Gene Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fvets.2020.00080","article-title":"Canine Models of Inherited Musculoskeletal and Neurodegenerative Diseases","volume":"7","author":"Story","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/joim.12469","article-title":"Genome editing in nonhuman primates: Approach to generating human disease models","volume":"280","author":"Chen","year":"2016","journal-title":"J. Intern. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.stem.2016.06.003","article-title":"Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing","volume":"19","author":"Sasaki","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/hum.2017.163","article-title":"Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease","volume":"29","author":"Randle","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/hum.2020.038","article-title":"Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease","volume":"31","author":"Aristorena","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/hum.2019.337","article-title":"Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-Linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy","volume":"31","author":"Song","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"107931","DOI":"10.1016\/j.heares.2020.107931","article-title":"Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction","volume":"394","author":"Hastings","year":"2020","journal-title":"Hear. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/bs.mcb.2021.11.001","article-title":"In vivo experimental mouse model to test CD19CAR T cells generated with different methods","volume":"167","author":"Myhre","year":"2022","journal-title":"Methods Cell Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.omto.2021.12.019","article-title":"Anti-CAIX BB\u03b6 CAR4\/8 T cells exhibit superior efficacy in a ccRCC mouse model","volume":"24","author":"Wang","year":"2022","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e003441","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b4 1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2014-11-570218","article-title":"Xenograft models for normal and malignant stem cells","volume":"125","author":"Goyama","year":"2015","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"113692","DOI":"10.1016\/j.bcp.2019.113692","article-title":"Mouse models in hematopoietic stem cell gene therapy and genome editing","volume":"174","author":"Radtke","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood-2006-05-023507","article-title":"Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects","volume":"108","author":"Mortellaro","year":"2006","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4049\/jimmunol.173.2.1380","article-title":"A 3 Adenosine Receptor Signaling Contributes to Airway Inflammation and Mucus Production in Adenosine Deaminase-Deficient Mice","volume":"173","author":"Young","year":"2004","journal-title":"J. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1074\/jbc.273.9.5093","article-title":"Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency","volume":"273","author":"Blackburn","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/mt.2014.240","article-title":"Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates","volume":"23","author":"Walia","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Massaro, G., Geard, A.F., Liu, W., Coombe-tennant, O., Waddington, S.N., Baruteau, J., Gissen, P., and Rahim, A.A. (2021). Gene therapy for lysosomal storage disorders: Ongoing studies and clinical development. Biomolecules, 11.","DOI":"10.3390\/biom11040611"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/mt.2012.23","article-title":"Preclinical Safety and Efficacy of human CD34 + Cells transduced with lentiviral vector for the treatment of wiskott-aldrich syndrome","volume":"21","author":"Scaramuzza","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05547.x","article-title":"Humanized mouse models of Cooley\u2019s anemia: Correct fetal-to-adult hemoglobin switching, disease onset, and disease pathology","volume":"1202","author":"Huo","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1074\/jbc.M805681200","article-title":"Humanized Mouse Model of Cooley\u2019s Anemia","volume":"284","author":"Huo","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"9259","DOI":"10.1073\/pnas.92.20.9259","article-title":"Mouse model of human beta zero thalassemia: Targeted deletion of the mouse beta maj-and beta min-globin genes in embryonic stem cells","volume":"92","author":"Ciavatta","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.1038\/s41598-019-48078-4","article-title":"In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI Techniques","volume":"9","author":"Shangaris","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1182\/blood-2008-12-197012","article-title":"Preclinical transfusion-dependent humanized mouse model of beta thalassemia major","volume":"113","author":"Huo","year":"2009","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.ejhg.5201535","article-title":"Large animal models and gene therapy","volume":"14","author":"Casal","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.3748\/wjg.v21.i16.4779","article-title":"Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease","volume":"21","author":"Chinnadurai","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.stemcr.2014.05.003","article-title":"Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo","volume":"3","author":"Chinnadurai","year":"2014","journal-title":"Stem Cell Rep."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4110\/in.2014.14.2.81","article-title":"Preclinical Efficacy and Mechanisms of Mesenchymal Stem Cells in Animal Models of Autoimmune Diseases","volume":"14","author":"Lee","year":"2014","journal-title":"Immune Netw."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3892\/etm.2021.10406","article-title":"Evaluation of animal models of Crohn\u2019s disease with anal fistula (Review)","volume":"22","author":"Lu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"654885","DOI":"10.3389\/fcell.2021.654885","article-title":"Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy","volume":"9","author":"Harman","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s12015-020-10053-2","article-title":"Spatio-Temporal Metabolokinetics and Efficacy of Human Placenta-Derived Mesenchymal Stem\/Stromal Cells on Mice with Refractory Crohn\u2019s-like Enterocutaneous Fistula","volume":"16","author":"Hou","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.omtn.2021.07.009","article-title":"mRNA-engineered mesenchymal stromal cells expressing CXCR2 enhances cell migration and improves recovery in IBD","volume":"26","author":"Li","year":"2021","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"658.e1","DOI":"10.1016\/j.jtct.2021.04.018","article-title":"Reduction of Graft-versus-Host-Disease in NOD.Cg-Prkdcscid Il2rgtm1Wjl\/SzJ. (NSG) Mice by Cotransplantation of Syngeneic Human Umbilical Cord-Derived Mesenchymal Stromal Cells: M","volume":"27","author":"Hansen","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/sctm.19-0193","article-title":"Are all stem cells equal? Systematic review, evidence map, and meta-analyses of preclinical stem cell-based therapies for bronchopulmonary dysplasia","volume":"9","author":"Augustine","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1573396314666180911100503","article-title":"The Therapeutic Potential of Stem Cells for Bronchopulmonary Dysplasia: \u201cIt\u2019s About Time\u201d or \u201cNot so Fast\u201d?","volume":"14","author":"Ee","year":"2018","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1164\/rccm.200902-0242OC","article-title":"Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease","volume":"180","author":"Aslam","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1152\/ajplung.00347.2011","article-title":"Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia","volume":"302","author":"Tropea","year":"2012","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/2045-8932.97603","article-title":"Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension","volume":"2","author":"Hansmann","year":"2012","journal-title":"Pulm. Circ."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1399-3046.2012.01709.x","article-title":"Bone marrow mesenchymal stem cells attenuate lung inflammation of hyperoxic newborn rats","volume":"16","author":"Zhang","year":"2012","journal-title":"Pediatr. Transplant."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-2600(18)30344-8","article-title":"Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): An international, observational study","volume":"7","author":"Khemani","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Behnke, J., Kremer, S., Shahzad, T., Chao, C.M., B\u00f6ttcher-Friebertsh\u00e4user, E., Morty, R.E., Bellusci, S., and Ehrhardt, H. (2020). MSC based therapies\u2014new perspectives for the injured lung. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030682"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.reth.2021.09.001","article-title":"A review and update for registered clinical studies of stem cells for non-tumorous and non-hematological diseases","volume":"18","author":"Chen","year":"2021","journal-title":"Regen. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2008.04.022","article-title":"Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis","volume":"213","author":"Sondhi","year":"2008","journal-title":"Exp. Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/mt.2013.138","article-title":"A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS gene therapy in Canavan mice","volume":"21","author":"Ahmed","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.mt.6300249","article-title":"Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease","volume":"15","author":"Roskelley","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"16036","DOI":"10.1038\/mtm.2016.36","article-title":"Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery","volume":"3","author":"Fu","year":"2016","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.actbio.2021.02.028","article-title":"Effects of recipient age, heparin release and allogeneic bone marrow-derived stromal cells on vascular graft remodeling","volume":"125","author":"Johnson","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ymthe.2005.07.358","article-title":"Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice","volume":"12","author":"Themis","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/mt.2012.224","article-title":"The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis","volume":"21","author":"Nowrouzi","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"eaba1028","DOI":"10.1126\/sciadv.aba1028","article-title":"Ionizable lipid nanoparticles for in utero mRNA delivery","volume":"7","author":"Riley","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneumeth.2004.09.027","article-title":"Targeted gene delivery to telencephalic inhibitory neurons by directional in utero electroporation","volume":"143","author":"Borrell","year":"2005","journal-title":"J. Neurosci. Methods"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/hgtb.2013.143","article-title":"In utero lung gene transfer using adeno-associated viral and lentiviral vectors in mice","volume":"25","author":"Joyeux","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/sj.mt.6300219","article-title":"Persistent expression of hF.IX after tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice","volume":"15","author":"Sabatino","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1038\/s41467-021-24443-8","article-title":"In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease","volume":"12","author":"Bose","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1096\/fj.201801391R","article-title":"Therapeutic expression of human clotting factors IX and \u00d7 following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques","volume":"33","author":"Chan","year":"2019","journal-title":"FASEB J."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"eaav8375","DOI":"10.1126\/scitranslmed.aav8375","article-title":"In utero gene editing for monogenic lung disease","volume":"11","author":"Alapati","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.exphem.2018.03.006","article-title":"A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe \u03b2-thalassemia in a HbbTh3\/+ murine model","volume":"62","author":"Dighe","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/s41467-018-04894-2","article-title":"In utero nanoparticle delivery for site-specific genome editing","volume":"9","author":"Ricciardi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/0963689717728937","article-title":"In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A","volume":"27","author":"Kumar","year":"2018","journal-title":"Cell Transplant."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0301-472X(02)01024-X","article-title":"Mixed chimerism following in utero hematopoietic stem cell transplantation in murine models of hemoglobinopathy","volume":"31","author":"Hayashi","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/mt.2009.200","article-title":"Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme","volume":"17","author":"Meza","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/stem.3039","article-title":"In Utero Transplantation of Expanded Autologous Amniotic Fluid Stem Cells Results in Long-Term Hematopoietic Engraftment","volume":"37","author":"Loukogeorgakis","year":"2019","journal-title":"Stem Cells"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/scd.2017.0116","article-title":"Long-Term Hematopoietic Engraftment of Congenic Amniotic Fluid Stem Cells After in Utero Intraperitoneal Transplantation to Immune Competent Mice","volume":"27","author":"Shangaris","year":"2018","journal-title":"Stem Cells Dev."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/SAP.0000000000000200","article-title":"Experience of using cultured epithelial autografts for the extensive burn wounds in eight patients","volume":"73","author":"Hayashi","year":"2014","journal-title":"Ann. Plast. Surg."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2325967119841077","article-title":"Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults","volume":"7","author":"Hoburg","year":"2019","journal-title":"Orthop. J. Sport. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nbt0612-479","article-title":"Gintuit cell therapy approval signals shift at US regulator","volume":"30","author":"Schmidt","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_184","first-page":"e3380","article-title":"Clinical Analysis of Cultured Epidermal Autograft (JACE) Transplantation for Giant Congenital Melanocytic Nevus","volume":"9","author":"Takaya","year":"2021","journal-title":"Plast. Reconstr. Surg.-Glob. Open"},{"key":"ref_185","first-page":"e16226","article-title":"Apligraf as an Alternative to Skin Grafting in the Pediatric Population","volume":"13","author":"Eudy","year":"2021","journal-title":"Cureus"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1089\/hum.2019.049","article-title":"Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial","volume":"30","author":"Di","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients with Recessive Dystrophic Epidermolysis Bullosa","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"key":"ref_190","unstructured":"European Medicines Agency (2021, December 30). PRIME: Priority Medicines|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/prime-priority-medicines."},{"key":"ref_191","unstructured":"Inacio, P. (2022, February 28). Amicus Discontinues Gene Therapy Program for CLN6 Batten Disease. Available online: https:\/\/battendiseasenews.com\/2022\/01\/21\/amicus-discontinues-cln6-gene-therapy-program\/."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European Medicines Agency. Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.addr.2014.02.010","article-title":"Gene and cell therapy for children--new medicines, new challenges?","volume":"73","author":"Buckland","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent \u00df-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nat. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/d41586-018-07643-z","article-title":"Prenatal gene therapy offers the earliest possible cure","volume":"564","author":"DeWeerdt","year":"2018","journal-title":"Nature"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe\u2019s Disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/mt.2016.20","article-title":"Timing of Gene Therapy Interventions: The Earlier, the Better","volume":"24","author":"Gray","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_198","first-page":"793","article-title":"Value-based pricing for emerging gene therapies: The economic case for a higher cost-effectiveness threshold","volume":"25","author":"Garrison","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Conti, R., Gruber, J., Ollendorf, D., and Neumann, P. (2021). Valuing Rare Pediatric Drugs: An Economics Perspective. SSRN Electron. J., NBER Working Paper No. w27978.","DOI":"10.3386\/w27978"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2021010864","article-title":"The cost-effectiveness of gene therapy for severe hemophilia B: A microsimulation study from the United States perspective","volume":"138","author":"Bolous","year":"2021","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: Paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: Long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"738204","DOI":"10.3389\/fimmu.2021.738204","article-title":"Aging of the Hematopoietic Stem Cell Niche: New Tools to Answer an Old Question","volume":"12","author":"Matteini","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/bmb\/ldr051","article-title":"Cell-based therapies for lung disease","volume":"101","author":"Garcia","year":"2012","journal-title":"Br. Med. Bull."},{"key":"ref_205","unstructured":"(2021, December 30). Alofisel|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alofisel."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3324\/haematol.2015.140368","article-title":"Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: A multicenter survey","volume":"101","author":"Kreyenberg","year":"2016","journal-title":"Haematologica"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","article-title":"Allogeneic human mesenchymal stem cell therapy (Remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients","volume":"20","author":"Kurtzberg","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2010.03.017","article-title":"Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population","volume":"16","author":"Lucchini","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbmt.2010.04.014","article-title":"Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (ProchymalTM) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease in a Compassionate Use Study","volume":"17","author":"Prasad","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/j.bbmt.2009.12.425","article-title":"Treatment Of Steroid-Refractory Acute GVHD with Mesenchymal Stem Cells Improves Outcomes In Pediatric Patients; Results Of The Pediatric Subset In A Phase III Randomized, Placebo-Controlled Study","volume":"16","author":"Zilberberg","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bmt.2008.348","article-title":"Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial","volume":"43","author":"MacMillan","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/bmt.2013.7","article-title":"Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation","volume":"48","author":"Lee","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/bmt.2010.87","article-title":"Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation","volume":"46","author":"Bernardo","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_214","first-page":"17","article-title":"\u201cNew\u201d bronchopulmonary dysplasia and chronic lung disease","volume":"24","author":"Voynow","year":"2017","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_215","first-page":"33","article-title":"Cell Therapy for Bronchopulmonary Dysplasia: Promises and Perils","volume":"20","year":"2016","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1152\/ajplung.00234.2009","article-title":"Hyperoxia disrupts vascular endothelial growth factor-nitric oxide signaling and decreases growth of endothelial colony-forming cells from preterm infants","volume":"297","author":"Fujinaga","year":"2009","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jpeds.2013.12.011","article-title":"Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial","volume":"164","author":"Chang","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jpeds.2017.02.061","article-title":"Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia","volume":"185","author":"Ahn","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_219","unstructured":"Medipost Co Ltd (2021, December 08). Long-Term Safety and Efficacy Follow-Up Study of PNEUMOSTEM\u00ae in Patients Who Completed PNEUMOSTEM\u00ae Phase-I Study, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02023788."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jpeds.2019.02.029","article-title":"Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants","volume":"210","author":"Powell","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/PCC.0000000000000350","article-title":"Pediatric Acute Respiratory Distress Syndrome: Consensus Recommendations from the Pediatric Acute Lung Injury Consensus Conference","volume":"16","author":"Jouvet","year":"2015","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.pcl.2017.06.004","article-title":"Pathophysiology and Management of Acute Respiratory Distress Syndrome in Children","volume":"64","author":"Heidemann","year":"2017","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMra1608077","article-title":"Acute Respiratory Distress Syndrome","volume":"377","author":"Thompson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","article-title":"Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial","volume":"3","author":"Wilson","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-2600(18)30477-6","article-title":"Cell-based therapies for acute respiratory distress syndrome","volume":"7","author":"Weiss","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","article-title":"Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): A randomised phase 2a safety trial","volume":"7","author":"Matthay","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2021-146100","article-title":"Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)","volume":"138","author":"Ahmed","year":"2021","journal-title":"Blood"},{"key":"ref_228","unstructured":"Tessa Therapeutics (2022, March 21). Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients with Relapsed\/Refractory Hodgkin Lymphoma (CHARIOT), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04268706."},{"key":"ref_229","unstructured":"Nichols, H., and Eides, R. (2022, March 21). Vertex and CRISPR Therapeutics Present New Data in 22 Patients with Greater than 3 Months Follow-Up Post-Treatment with Investigational CRISPR\/Cas9 Gene-Editing Therapy, CTX001TM. Available online: https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-and-crispr-therapeutics-present-new-data-22-patients."},{"key":"ref_230","unstructured":"CRISPRTX (2022, March 21). A Safety and Efficacy Study Evaluating CTX001 in Subjects with Severe Sickle Cell Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03745287."},{"key":"ref_231","unstructured":"Aiuiti, A and IRCCS San Raffaele (2022, February 27). Gene Therapy for Transfusion Dependent Beta-thalassemia (TIGET-BTHAL), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02453477."},{"key":"ref_232","unstructured":"Orchard Therapeutics (2022, March 21). Long-Term Follow-Up of Subjects Treated with OTL-300 for Transfusion-Dependent Beta-Thalassemia Study (TIGET-BTHAL), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03275051."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2021-151898","article-title":"A Phase 1\/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Interim Results","volume":"138","author":"Kohn","year":"2021","journal-title":"Blood"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-142484","article-title":"A Phase 1\/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1","volume":"136","author":"Kohn","year":"2020","journal-title":"Blood"},{"key":"ref_235","unstructured":"Rocket Pharmaceuticals Inc (2022, March 21). A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects with Leukocyte Adhesion Deficiency-I, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03812263."},{"key":"ref_236","unstructured":"Aiuiti, A and IRCCS San Raffaele (2022, March 21). Gene Therapy with Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients with Mucopolysaccharidosis Type I, Hurler Variant (TigetT10_MPSIH), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03488394."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic Stem-and Progenitor-Cell Gene Therapy for Hurler Syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_238","unstructured":"National Institutes of Health Clinical Center (CC) and National Institute of Allergy and Infectious Diseases (NIAID) (2022, March 21). Lentiviral Gene Transfer for Treatment of Children Older than 2 Years of Age with X-Linked Severe Combined Immunodeficiency (LVXSCID-OC), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01306019."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood-2019-127439","article-title":"Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency","volume":"134","author":"Kwatemaa","year":"2019","journal-title":"Blood"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_241","unstructured":"St. Jude Children\u2032s Research Hospital (2022, March 21). Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01512888."},{"key":"ref_242","unstructured":"ExCellThera Inc (2022, March 21). US Phase I Study of ECT-001-CB in Patients with Sickle-Cell Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT04594031."},{"key":"ref_243","unstructured":"ExCellThera Inc (2022, March 21). US Study of ECT-001-CB in Pediatric and Young Adult Patients with High-Risk Myeloid Malignancies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04990323."},{"key":"ref_244","unstructured":"Rocket Pharmaceuticals Inc (2022, March 21). A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects with Fanconi Anemia Subtype A, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03814408."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1182\/blood-2019-127352","article-title":"Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-VivoFANCA Gene Insertion in Human Stem and Progenitor Cells","volume":"134","author":"Czechowicz","year":"2019","journal-title":"Blood"},{"key":"ref_246","unstructured":"Rocket Pharmaceuticals Inc (2022, March 21). Gene Therapy for Fanconi Anemia, Complementation Group A, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04248439."},{"key":"ref_247","unstructured":"Rocket Pharmaceuticals Inc (2022, March 21). Lentiviral-Mediated Gene Therapy for Pediatric Patients with Fanconi Anemia Subtype A, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04069533."},{"key":"ref_248","unstructured":"bluebird bio (2022, March 21). Longterm Follow-Up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02633943."},{"key":"ref_249","unstructured":"AlloVir (2022, March 21). Study of Viralym-M (ALVR105) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04693637."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2021-152553","article-title":"Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial","volume":"138","author":"Dadwal","year":"2021","journal-title":"Blood"},{"key":"ref_251","unstructured":"AlloVir (2022, March 21). Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04390113."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1093\/emboj\/20.23.6877","article-title":"Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate","volume":"20","author":"Elbashir","year":"2001","journal-title":"EMBO J."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/sctm.20-0330","article-title":"Stem cells for bronchopulmonary dysplasia in preterm infants: A randomized controlled phase II trial","volume":"10","author":"Ahn","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"ref_254","unstructured":"Medipost Co Ltd (2021, December 08). Follow-Up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM\u00ae Phase-II Clinical Trial, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01897987."},{"key":"ref_255","unstructured":"Lee Farmer, D., and University of California, Davis (2021, December 11). Cellular Therapy for In Utero Repair of Myelomeningocele\u2014The CuRe Trial, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04652908."},{"key":"ref_256","unstructured":"G\u00f6therstr\u00f6m, C and Karolinska Institutet (2021, December 11). Boost Brittle Bones before Birth (BOOSTB4), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03706482."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1714322","article-title":"Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia","volume":"378","author":"Schneider","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/pd.4966","article-title":"Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: A case series and review of the literature","volume":"36","author":"Kreger","year":"2016","journal-title":"Prenat. Diagn."},{"key":"ref_259","unstructured":"Mackenzie, T., and University of California, San Francisco (2021, December 11). In Utero Hematopoietic Stem Cell Transplantation for Alpha-Thalassemia Major (ATM), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02986698."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-142698","article-title":"In Utero Stem Cell Transplantation in Patients with Alpha Thalassemia Major: Interim Results of a Phase 1 Clinical Trial","volume":"136","author":"MacKenzie","year":"2020","journal-title":"Blood"},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Dimitri, P., Pignataro, V., Lupo, M., Bonifazi, D., Henke, M., Musazzi, U.M., Ernst, F., Minghetti, P., Redaelli, D.F., and Antimisiaris, S.G. (2021). Medical device development for children and young people\u2014reviewing the challenges and opportunities. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122178"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"28","DOI":"10.17925\/EOH.2017.13.01.28","article-title":"Clinical development and manufacture of chimeric antigen receptor T cells and the role of leukapheresis","volume":"13","author":"Fesnak","year":"2017","journal-title":"Eur. Oncol. Haematol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2007-01-068759","article-title":"Hot spots of retroviral integration in human CD34+ hematopoietic cells","volume":"110","author":"Cattoglio","year":"2007","journal-title":"Blood"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.1073\/pnas.95.20.11939","article-title":"HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0\/G1 human hematopoietic stem cells","volume":"95","author":"Uchida","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"720501","DOI":"10.3389\/fonc.2021.720501","article-title":"From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies","volume":"11","author":"Lu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1089\/15258160152509145","article-title":"Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92","volume":"10","author":"Tonn","year":"2001","journal-title":"J. Hematother. Stem Cell Res."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2019-131373","article-title":"FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma","volume":"134","author":"Bjordahl","year":"2019","journal-title":"Blood"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2019-129319","article-title":"FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies","volume":"134","author":"Goodridge","year":"2019","journal-title":"Blood"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488808786734033","article-title":"Hematopoietic Stem Cells: Source Matters","volume":"3","author":"Haspel","year":"2008","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2011-04-349688","article-title":"Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: A prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study","volume":"119","author":"Styczynski","year":"2012","journal-title":"Blood"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5603\/AHP.2021.0045","article-title":"Autologous hematopoietic stem cell transplantation (auto-HSCT) in children in Poland: 2021 indications and practice","volume":"52","author":"Drabko","year":"2021","journal-title":"Acta Haematol. Pol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.transci.2016.09.014","article-title":"Comprehensive technical and patient-care optimization in the management of pediatric apheresis for peripheral blood stem cell harvesting","volume":"55","author":"Ohara","year":"2016","journal-title":"Transfus. Apher. Sci."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.transci.2015.05.010","article-title":"Stem cell mobilization and collection from pediatric patients and healthy children","volume":"53","author":"Karakukcu","year":"2015","journal-title":"Transfus. Apher. Sci."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1034\/j.1399-3046.7.s3.10.x","article-title":"Peripheral blood as a stem cell source for hematopoietic cell transplantation in children: Is the effort in vein?","volume":"7","author":"Lipton","year":"2003","journal-title":"Pediatr. Transplant."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.12688\/f1000research.21129.1","article-title":"Mobilized peripheral blood: An updated perspective","volume":"8","author":"DiPersio","year":"2019","journal-title":"F1000Research"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"103005","DOI":"10.1016\/j.transci.2020.103005","article-title":"Reduced volume of red blood cell priming is safe for pediatric patients undergoing therapeutic plasma exchange","volume":"60","author":"Luzzi","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13287-021-02379-6","article-title":"Comparison of the efficacy of hematopoietic stem cell mobilization regimens: A systematic review and network meta-analysis of preclinical studies","volume":"12","author":"Luo","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Tajer, P., Pike-Overzet, K., Arias, S., Havenga, M., and Staal, F. (2019). Ex Vivo Expansion of Hematopoietic Stem Cells for Therapeutic Purposes: Lessons from Development and the Niche. Cells, 8.","DOI":"10.3390\/cells8020169"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/stem.1957","article-title":"Enrichment of human hematopoietic stem\/progenitor cells facilitates transduction for stem cell gene therapy","volume":"33","author":"Baldwin","year":"2015","journal-title":"Stem Cells"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"e00191","DOI":"10.1042\/BSR20150025","article-title":"Human mesenchymal stem cells-Current trends and future prospective","volume":"35","author":"Ullah","year":"2015","journal-title":"Biosci. Rep."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bone.2019.03.041","article-title":"Aging and lineage allocation changes of bone marrow skeletal (stromal)stem cells","volume":"123","author":"Nehlin","year":"2019","journal-title":"Bone"},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Seo, Y., Shin, T.H., and Kim, H.S. (2019). Current strategies to enhance adipose stem cell function: An update. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153827"},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Kuca-Warnawin, E., Skalska, U., Janicka, I., Musia\u0142owicz, U., Bonek, K., G\u0142uszko, P., Szcz\u0119sny, P., Olesi\u0144ska, M., and Kontny, E. (2019). The Phenotype and Secretory Activity of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Patients with Rheumatic Diseases. Cells, 8.","DOI":"10.3390\/cells8121659"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3727\/096368915X686841","article-title":"Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy","volume":"24","author":"Ding","year":"2015","journal-title":"Cell Transplant."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1093\/hmg\/ddn052","article-title":"Stem cell-based strategies for treating pediatric disorders of myelin","volume":"17","author":"Goldman","year":"2008","journal-title":"Hum Mol. Genet"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000479157","article-title":"Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases","volume":"58","author":"Peng","year":"2017","journal-title":"Ophthalmic Res."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fphar.2014.00270","article-title":"In utero therapy for congenital disorders using amniotic fluid stem cells","volume":"5","author":"Ramachandra","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_289","first-page":"GE01","article-title":"Non Viral Vectors in Gene Therapy-An Overview","volume":"9","author":"Biological","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_290","first-page":"3","article-title":"Non-viral and viral vectors for gene therapy","volume":"51","author":"Boulaiz","year":"2005","journal-title":"Cell. Mol. Biol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.hoc.2017.06.001","article-title":"In Vivo Hematopoietic Stem Cell Transduction","volume":"31","author":"Richter","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Murai, N., Ohtaki, H., Watanabe, J., Xu, Z., Sasaki, S., Yagura, K., Shioda, S., Nagasaka, S., Honda, K., and Izumizaki, M. (2017). Intrapancreatic injection of human bone marrow-derived mesenchymal stem\/stromal cells alleviates hyperglycemia and modulates the macrophage state in streptozotocin-induced type 1 diabetic mice. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186637"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/bloodadvances.2020003702","article-title":"In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal \u03b3-globin in \u03b2-YAC mice","volume":"5","author":"Li","year":"2021","journal-title":"Blood Adv."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"70.e1","DOI":"10.1016\/j.jtct.2021.11.010","article-title":"Engraftment Effects after Intra-Bone Marrow versus Intravenous Allogeneic Stem Cell Transplantation in a Reduced-Intensity Conditioning Dog Leukocyte Antigen-Identical Canine Model","volume":"28","author":"Schaefer","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coviro.2021.03.006","article-title":"Adenovirus-a blueprint for gene delivery","volume":"48","author":"Greber","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2021.03.029","article-title":"BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment","volume":"333","author":"Chen","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.1038\/s41598-020-75206-2","article-title":"Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer","volume":"10","author":"Jacobs","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcyt.2020.08.012","article-title":"Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: Process validation and first in-human data","volume":"23","author":"Kerstan","year":"2021","journal-title":"Cytotherapy"},{"key":"ref_299","doi-asserted-by":"crossref","unstructured":"Weiss, R., Gerdes, W., Berthold, R., Sack, U., Koehl, U., Hauschildt, S., and Grahnert, A. (2021). Comparison of Three CD3-Specific Separation Methods Leading to Labeled and Label-Free T Cells. Cells, 10.","DOI":"10.3390\/cells10112824"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.20892\/j.issn.2095-3941.2021.0040","article-title":"Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies","volume":"18","author":"Han","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.3324\/haematol.2018.215178","article-title":"Correction of IVS I-110(G>A) \u03b2-thalassemia by CRISPR\/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells","volume":"104","author":"Patsali","year":"2019","journal-title":"Haematologica"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jcyt.2016.11.007","article-title":"Suitability of small diagnostic peripheral-blood samples for cell-therapy studies","volume":"19","author":"Stephanou","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13287-021-02406-6","article-title":"Nonviral genome engineering of natural killer cells","volume":"12","author":"Robbins","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15283\/ijsc20117","article-title":"Efficacy of Gene Modification in Placenta-Derived Mesenchymal Stem Cells Based on Nonviral Electroporation","volume":"14","author":"Kim","year":"2021","journal-title":"Int. J. Stem Cells"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ymthe.2018.01.012","article-title":"Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors","volume":"26","author":"Holstein","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ymthe.2018.10.008","article-title":"Optimization of CRISPR\/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements","volume":"27","author":"Lattanzi","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exphem.2021.01.003","article-title":"Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells","volume":"95","author":"Russkamp","year":"2021","journal-title":"Exp. Hematol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtm.2018.02.004","article-title":"Integrating HDAd5\/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies","volume":"9","author":"Li","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"key":"ref_312","first-page":"e62245","article-title":"Delivery of the Cas9\/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles (\u201cNanoblades\u201d)","volume":"169","author":"Mangeot","year":"2021","journal-title":"J. Vis. Exp."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00109-020-02034-2","article-title":"Evolving AAV-delivered therapeutics towards ultimate cures","volume":"99","author":"He","year":"2021","journal-title":"J. Mol. Med."},{"key":"ref_314","unstructured":"(2021, January 13). Definition-Nanomaterials-Environment-European Commission. Available online: https:\/\/ec.europa.eu\/environment\/chemicals\/nanotech\/faq\/definition_en.htm."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/NSA.S8984","article-title":"Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules","volume":"3","author":"DeLong","year":"2010","journal-title":"Nanotechnol. Sci. Appl."},{"key":"ref_317","doi-asserted-by":"crossref","unstructured":"Rai, R., Alwani, S., and Badea, I. (2019). Polymeric nanoparticles in gene therapy: New avenues of design and optimization for delivery applications. Polymers, 11.","DOI":"10.3390\/polym11040745"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-017-2286-0","article-title":"The Placental Barrier: The Gate and the Fate in Drug Distribution","volume":"35","author":"Tetro","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/nnm-2015-0012","article-title":"Nanoparticle transport across the placental barrier: Pushing the field forward","volume":"11","author":"Muoth","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"120580","DOI":"10.1016\/j.biomaterials.2020.120580","article-title":"PLGA-Nanoparticles for Intracellular Delivery of the CRISPR-Complex to Elevate Fetal Globin Expression in Erythroid Cells","volume":"268","author":"Cruz","year":"2021","journal-title":"Biomaterials"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"e1600349","DOI":"10.1126\/sciadv.1600349","article-title":"Tumor-homing peptides as tools for targeted delivery of payloads to the placenta","volume":"2","author":"King","year":"2016","journal-title":"Sci. Adv."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1210\/en.2012-1832","article-title":"Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies","volume":"154","author":"Pattison","year":"2013","journal-title":"Endocrinology"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1021\/acsbiomaterials.0c00826","article-title":"Nanoparticle-Mediated Simultaneous Downregulation of Placental Nrf2 and sFlt1 Improves Maternal and Fetal Outcomes in a Preeclampsia Mouse Model","volume":"6","author":"Li","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_324","unstructured":"(2021, January 13). EUR-Lex-32007R1394-EN-EUR-Lex. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/ALL\/?uri=CELEX%3A32007R1394."},{"key":"ref_325","unstructured":"(2021, January 13). Promising mRNA Tech Comes with Regulatory, CMC Headaches|RAPS. Available online: https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/11\/euro-convergence-regulatory-and-cmc-considerations."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.devcel.2020.05.025","article-title":"Persistent DNA Damage and Senescence in the Placenta Impacts Developmental Outcomes of Embryos","volume":"54","author":"Singh","year":"2020","journal-title":"Dev. Cell"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/humupd\/dmaa049","article-title":"Nanoparticles in pregnancy: The next frontier in reproductive therapeutics","volume":"27","author":"Pritchard","year":"2020","journal-title":"Hum. Reprod. Update"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1039\/D0TB00612B","article-title":"Design of nanomaterials for applications in maternal\/fetal medicine","volume":"8","author":"Nelson","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ng0395-243","article-title":"Gene transfer and expression in progeny after intravenous DNA injection into pregnant mice","volume":"9","author":"Tsukamoto","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/1061186X.2015.1055569","article-title":"Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes","volume":"24","author":"Cornford","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_331","doi-asserted-by":"crossref","unstructured":"Ellah, N.A., Taylor, L., Troja, W., Owens, K., Ayres, N., Pauletti, G., and Jones, H. (2015). Development of non-viral, trophoblast-specific gene delivery for placental therapy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140879"},{"key":"ref_332","doi-asserted-by":"crossref","unstructured":"Giubilato, E., Cazzagon, V., Amorim, M.J.B., Blosi, M., Bouillard, J., Bouwmeester, H., Costa, A.L., Fadeel, B., Fernandes, T.F., and Fito, C. (2020). Risk Management Framework for Nano-Biomaterials Used in Medical Devices and Advanced Therapy Medicinal Products. Materials, 13.","DOI":"10.3390\/ma13204532"},{"key":"ref_333","unstructured":"(2021, January 13). BIOmaterial RIsk MAnagement|BIORIMA Project|H2020|CORDIS|European Commission. Available online: https:\/\/cordis.europa.eu\/project\/id\/760928."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3389\/fimmu.2019.01645","article-title":"Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application","volume":"10","author":"Caplan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_335","doi-asserted-by":"crossref","unstructured":"Bonig, H., Ku\u00e7i, Z., Ku\u00e7i, S., Bakhtiar, S., Basu, O., Bug, G., Dennis, M., Greil, J., Barta, A., and K\u00e1llay, K.M. (2019). Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation \u201cMSC-FFM\u201d-Outcome Report of 92 Patients. Cells, 8.","DOI":"10.3390\/cells8121577"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/ped.14001","article-title":"Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia","volume":"61","author":"Namba","year":"2019","journal-title":"Pediatr. Int."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/hum.2019.197","article-title":"Public Acceptability of Gene Therapy and Gene Editing for Human Use: A Systematic Review","volume":"31","author":"Delhove","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"e9992","DOI":"10.15252\/emmm.201809992","article-title":"Innovation and competition in advanced therapy medicinal products","volume":"11","author":"Shukla","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jcyt.2017.06.009","article-title":"A roadmap for cost-of-goods planning to guide economic production of cell therapy products","volume":"19","author":"Lipsitz","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_340","doi-asserted-by":"crossref","unstructured":"Walpole, S.C., Prieto-Merino, D., Edwards, P., Cleland, J., Stevens, G., and Roberts, I. (2012). The weight of nations: An estimation of adult human biomass. BMC Public Health, 12.","DOI":"10.1186\/1471-2458-12-439"},{"key":"ref_341","first-page":"e74","article-title":"Standards for the measurement of birth weight, length and head circumference at term in neonates of European, Chinese and South Asian ancestry","volume":"1","author":"Janssen","year":"2007","journal-title":"Open Med."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/stem.1839","article-title":"Sheep CD34+ amniotic fluid cells have hematopoietic potential and engraft after autologous in utero transplantation","volume":"33","author":"Shaw","year":"2015","journal-title":"Stem Cells"},{"key":"ref_343","doi-asserted-by":"crossref","unstructured":"Aurich, B., and Jacqz-Aigrain, E. (2021). Drug safety in translational paediatric research: Practical points to consider for paediatric safety profiling and protocol development: A scoping review. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050695"},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00228-006-0193-0","article-title":"Medicines for children licensed by the European Medicines Agency. (EMEA): The balance after 10 years","volume":"62","author":"Ceci","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-017-0617-1","article-title":"Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: An increased common effort is to be foreseen","volume":"12","author":"Giannuzzi","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_346","unstructured":"(2021, October 26). TEDDY \u2013 European Network of Excellence for Paediatric Clinical Research. European Paediatric Medicines Database (EPMD). Available online: https:\/\/www.teddynetwork.net\/european-paediatric-medicines-database-epmd\/."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14023","article-title":"Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns","volume":"27","author":"Pierce","year":"2021","journal-title":"Haemophilia"},{"key":"ref_348","doi-asserted-by":"crossref","unstructured":"Brooks, S.P., and Bubela, T. (2020). Application of protection motivation theory to clinical trial enrolment for pediatric chronic conditions. BMC Pediatr., 20.","DOI":"10.1186\/s12887-020-2014-5"},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","article-title":"Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones","volume":"28","author":"Bushman","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_350","doi-asserted-by":"crossref","unstructured":"(2021). Gene therapy needs a long-term approach. Nat. Med., 27, 563.","DOI":"10.1038\/s41591-021-01333-6"},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"613252","DOI":"10.3389\/fgeed.2020.613252","article-title":"Gene Editing and Genotoxicity: Targeting the Off-Targets","volume":"2","author":"Blattner","year":"2020","journal-title":"Front. Genome Ed."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ymthe.2019.02.015","article-title":"In Utero Gene Therapy Consensus Statement from the IFeTIS","volume":"27","author":"Waddington","year":"2019","journal-title":"Mol. Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:57Z","timestamp":1760136597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":352,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pharmaceutics14040793"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14040793","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]}}}